Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cogent Biosciences stock

Learn how to easily invest in Cogent Biosciences stock.

Cogent Biosciences is a biotechnology business based in the US. Cogent Biosciences shares (COGT) are listed on the NASDAQ and all prices are listed in US Dollars. Cogent Biosciences employs 121 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Cogent Biosciences stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – COGT. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Cogent Biosciences stock price (NASDAQ: COGT)

Use our graph to track the performance of COGT stocks over time.

Cogent Biosciences shares at a glance

Information last updated 2023-01-19.
Latest market close$14.84
52-week range$3.79 - $18.07
50-day moving average $11.75
200-day moving average $11.08
Wall St. target price$22.14
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.21

Buy Cogent Biosciences stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Cogent Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cogent Biosciences price performance over time

Historical closes compared with the close of $14.84 from 2023-01-25

1 week (2023-01-20) 10.66%
1 month (2022-12-27) 37.66%
3 months (2022-10-27) 9.93%
6 months (2022-07-27) 32.97%
1 year (2022-01-23) N/A
2 years (2021-01-27) 54.58%
3 years (2020-01-27) 1,414.44%
5 years (2018-01-23) N/A

Cogent Biosciences financials

Gross profit TTM $-55,913,000
Return on assets TTM -29.65%
Return on equity TTM -51.54%
Profit margin 0%
Book value $3.21
Market capitalisation $880.7 million

TTM: trailing 12 months

Cogent Biosciences share dividends

We're not expecting Cogent Biosciences to pay a dividend over the next 12 months.

Have Cogent Biosciences's shares ever split?

Cogent Biosciences's shares were split on a 1:4 basis on 9 November 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cogent Biosciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Cogent Biosciences shares which in turn could have impacted Cogent Biosciences's share price.

Cogent Biosciences share price volatility

Over the last 12 months, Cogent Biosciences's shares have ranged in value from as little as $3.79 up to $18.07. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cogent Biosciences's is -0.5813. This would suggest that Cogent Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cogent Biosciences has bucked the trend.

Cogent Biosciences overview

Cogent Biosciences, Inc. , a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc.

Frequently asked questions

What percentage of Cogent Biosciences is owned by insiders or institutions?
Currently 0.007% of Cogent Biosciences shares are held by insiders and 110.14% by institutions.
How many people work for Cogent Biosciences?
Latest data suggests 121 work at Cogent Biosciences.
When does the fiscal year end for Cogent Biosciences?
Cogent Biosciences's fiscal year ends in December.
Where is Cogent Biosciences based?
Cogent Biosciences's address is: 200 Cambridge Park Drive, Cambridge, MA, United States, 02140
What is Cogent Biosciences's ISIN number?
Cogent Biosciences's international securities identification number is: US19240Q2012

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site